Brief: Talaris Therapeutics Provides Update On Freedom-1 Phase 3 Clinical Trial

Tourmaline Bio

20/10/2022 12:54

Oct 20 (Reuters) - Talaris Therapeutics Inc  TALS.O :
    * TALARIS THERAPEUTICS PROVIDES UPDATE ON FREEDOM-1 PHASE 3
CLINICAL TRIAL
    * TALARIS THERAPEUTICS -REPORT OF PATIENT DEATH, TRIGGERED
PRE-SPECIFIED, TEMPORARY STOPPING REQUIREMENT & REVIEW BY
FREEDOM-1 DATA MONITORING COMMITTEE
    * TALARIS THERAPEUTICS INC- AFTER THEIR REVIEW OF THIS CASE,
DMC
DETERMINED THAT TRIAL ENROLLMENT AND DOSING MAY CONTINUE

Source text for Eikon:  ID:nGNX2285Cq 
Further company coverage:  TALS.O 
 ((Reuters.Briefs@thomsonreuters.com;;))